Abstract:Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatric disorders. Preclinical reports suggest that the biological effects of psilocybin-containing mushroom extract or "full spectrum" (psychedelic) mushroom extract (PME), may differ from those of chemically synthesized psilocybin (PSIL). We compared the effects of PME to those of PSIL on the head twitch response (HTR), neuroplasticity-related synaptic proteins and frontal cortex metabolomic profiles in male C57Bl/6j mice. HTR measurement showed similar effects of PSIL and PME over 20 min. Brain specimens (frontal cortex, hippocampus, amygdala, striatum) were assayed for the synaptic proteins, GAP43, PSD95, synaptophysin and SV2A, using western blots. These proteins may serve as indicators of synaptic plasticity. Three days after treatment, there was minimal increase in synaptic proteins. After 11 days, PSIL and PME significantly increased GAP43 in the frontal cortex ( p = 0.019; p = 0.039 respectively) and hippocampus ( p = 0.015; p = 0.027) and synaptophysin in the hippocampus ( p = 0.041; p = 0.05) and amygdala ( p = 0.035; p = 0.004). PSIL increased SV2A in the amygdala ( p = 0.036) and PME did so in the hippocampus ( p = 0.014). In the striatum, synaptophysin was increased by PME only ( p = 0.023). There were no significant effects of PSIL or PME on PSD95 in any brain area when these were analyzed separately. Nested analysis of variance (ANOVA) showed a significant increase in each of the 4 proteins over all brain areas for PME versus vehicle control, while significant PSIL effects were observed only in the hippocampus and amygdala and were limited to PSD95 and SV2A. Metabolomic analyses of the pre-frontal cortex were performed by untargeted polar metabolomics utilizing capillary electrophoresis – Fourier transform mass spectrometry (CE-FTMS) and showed a differential metabolic separation between PME and vehicle groups. The purines guanosine, hypoxanthine and inosine, associated with oxidative stress and energy production pathways, showed a progressive decline from VEH to PSIL to PME. In conclusion, our synaptic protein findings suggest that PME has a more potent and prolonged effect on synaptic plasticity than PSIL. Our metabolomics data support a gradient of effects from inert vehicle via chemical psilocybin to PME further supporting differential effects. Further studies are needed to confirm and extend these findings and to identify the molecules that may be responsible for the enhanced effects of PME as compared to psilocybin alone.

Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants

Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report

Inhaled Dimethyltryptamine (DMT): Use Patterns and Predictors of Consumption Frequency

Effects of DMT on mental health outcomes in healthy volunteers

Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience

Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects

Psilocin Suppresses Methamphetamine‐induced Hyperlocomotion and Acquisition of Conditioned Place Preference Via D2R‐mediated ERK Signaling

Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain

The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption

Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans

Classics in Chemical Neuroscience: Dextromethorphan (DXM)

Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects

Psilocybin desynchronizes brain networks

The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin

Psilocybin desynchronizes the human brain

Pharmacological and behavioural effects of tryptamines present in psilocybin‐containing mushrooms

Acute effects of R -MDMA, S -MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants

Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat

In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin